Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in France / NCT06391684
Recruiting Observational

Flexibility and the Predictive Brain in Autistic Males and Females

NCT06391684 · tracked via the Priya Life Science France tracker
Phase
Observational
Started
2025-02-21
Last updated
2026-10-02

Condition(s) studied

Autism Spectrum Disorder

Investigational drug(s) / intervention(s)

Social/non social; predictable vs unpredictable

Social/non social; predictable vs unpredictable: Task 1: social predictable vs social unpredictable ; Task2 a. social \& b. non social, predictable/unpredictable (for both)

Study summary

The goal of this study is to compare the neural correlates of predictive brain mechanisms during high-level social and non-social flexibility tasks, between autistic and non-autistic males and females. The aim is to better understand if autistic individuals differ from non-autistic individuals in their cognitive flexibility according to the social and predictable nature of the stimuli, at a behavioral and neurofunctional level using the functional Magnetic Resonance Imaging (fMRI). As autistic females usually present a more subtle profile than autistic males, the investigators will also explore if autistic males and females present neurofunctional differences.

Eligibility

Sex
ALL
Min age
18 Years
Max age
50 Years
Healthy volunteers
Accepted
Inclusion Criteria: For non autistic individuals * Affiliation with social security scheme. * Registration in the national database of individuals willing to participate in research involving human subjects. * Absence of contraindications for MRI. * Signed informed consent before any study-related procedure. * Visual acuity allowing normal perception of stimuli or corrected vision. * Autism Quotient (AQ) (Baron-Cohen et al., 2001) \< 32. For autistic individuals: * Affiliation with social security scheme. * Absence of contraindications for MRI. * Signed informed consent before any study-related procedure. * Visual acuity allowing normal perception of stimuli or corrected vision. * Diagnosis of autism established by a competent professional based on DSM/ICD criteria. Exclusion Criteria: * Any subject with a vascular stent implanted less than 6 weeks before the examination. * Any subject with implanted biomedical material deemed "unsafe" or "not safe" in the list: http://www.mrisafety.com/TheList\_search.asp. * Any acquisition procedure not meeting the conditions required for "conditional" use in subjects with implanted biomedical material classified as "conditional" in the list: http://www.mrisafety.com/TheList\_search.asp. * Any subject with biomedical material such as a cardiac, neuronal, or sensory stimulator (cochlear implant due to the risk of demagnetization, heating, electrode, and artifacts) or a ventricular shunt valve without medical and paramedical supervision trained in MRI performance in these subjects. * Intraocular or intracranial ferromagnetic foreign body near nerve structures (risk of displacement and complications such as ocular or cerebral lesions). * Claustrophobia - Psychiatric or neurological conditions other than those specified. * Existence of a severe general health condition incompatible with the study: cardiac, respiratory, hematological, renal, hepatic, or cancerous. * Alcohol ingestion before the examination. * Persons covered by articles L1121-5 to L1121-8 of the Public Health Code (pregnant or breastfeeding women, minors or adults under legal protection, individuals under administrative or judicial surveillance). * Visual impairments. * Intellectual disability. * Inability to understand research instructions or provide informed consent.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
CHU Grenoble Alpes_DRCI_Pavillon Dauphiné_CS Grenoble France Recruiting

More University Hospital, Grenoble trials in France

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06391684 on ClinicalTrials.gov ↗ ← All trials in France